ESMO recap: Keeping TIGIT alive, Rybrevant & immunotherapy anniversary — a BioCentury podcast

Plus: Special guest Gwyn Bebb of Parexel on his conference takeaways, COVID vaccines for cancer and radiopharma

The ESMO Congress yielded another Phase II win for cancer immunotherapy target TIGIT, but the readout resurfaced worries about the mechanism’s past failures to turn positive Phase II data into Phase III success. On a special edition of the BioCentury This Week podcast, BioCentury’s Lauren Martz and Stephen Hansen deliver their takeaways from this year’s meeting, including analysis of data for Fc-enabled TIGIT blocker belrestotug from iTeos Therapeutics Inc. (NASDAQ:ITOS), a colorectal cancer readout featuring Rybrevant amivantamab from Johnson & Johnson (NYSE:JNJ), and an antibody-drug conjugate from Genmab A/S (CSE:GMAB; NASDAQ:GMAB).

The BioCentury team is joined by ESMO attendee Gwyn Bebb, who is SVP and global franchise head for oncology at podcast sponsor Parexel International Corp. Bebb discusses what’s changed in the oncology landscape in the 10 years since the approval of the first immunotherapies, observations that COVID-19 vaccines might have a role in treating cancer, and developments in the radiopharmaceutical field.

This episode of BioCentury This Week was sponsored by Parexel Biotech. For information on opportunities to sponsor The BioCentury Show and the BioCentury This Week podcast, please email conferences@biocentury.com.